Marshall Wace LLP Invests $212,000 in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Marshall Wace LLP bought a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 4,426 shares of the biopharmaceutical company's stock, valued at approximately $212,000.

Several other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in Halozyme Therapeutics by 3.0% during the 4th quarter. Vanguard Group Inc. now owns 13,281,714 shares of the biopharmaceutical company's stock valued at $634,999,000 after purchasing an additional 386,618 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in shares of Halozyme Therapeutics by 0.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,783,177 shares of the biopharmaceutical company's stock worth $85,254,000 after buying an additional 9,780 shares in the last quarter. Norges Bank bought a new position in shares of Halozyme Therapeutics during the fourth quarter worth $60,054,000. Arrowstreet Capital Limited Partnership grew its stake in Halozyme Therapeutics by 141.3% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 992,887 shares of the biopharmaceutical company's stock valued at $47,470,000 after acquiring an additional 581,475 shares in the last quarter. Finally, Boston Trust Walden Corp increased its holdings in Halozyme Therapeutics by 28.0% in the 4th quarter. Boston Trust Walden Corp now owns 874,081 shares of the biopharmaceutical company's stock valued at $41,790,000 after acquiring an additional 191,465 shares during the last quarter. Institutional investors own 97.79% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently weighed in on HALO shares. Wells Fargo & Company cut their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research report on Monday, January 13th. Benchmark reaffirmed a "buy" rating and issued a $75.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. HC Wainwright reiterated a "buy" rating and set a $72.00 target price on shares of Halozyme Therapeutics in a research report on Friday, April 25th. Piper Sandler boosted their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a research report on Friday, January 10th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a research report on Monday, April 21st. Four analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $62.89.

Halozyme Therapeutics Price Performance

HALO stock opened at $60.62 on Tuesday. The stock has a market cap of $7.49 billion, a PE ratio of 17.67, a P/E/G ratio of 0.42 and a beta of 1.26. Halozyme Therapeutics, Inc. has a 12 month low of $40.19 and a 12 month high of $66.00. The company has a 50-day moving average price of $60.85 and a 200 day moving average price of $55.46. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The business had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million. Equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 4,497 shares of the company's stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $60.37, for a total value of $271,483.89. Following the transaction, the director now directly owns 28,611 shares in the company, valued at $1,727,246.07. This represents a 13.58 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Michael J. Labarre sold 1,697 shares of Halozyme Therapeutics stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total transaction of $98,901.16. Following the sale, the senior vice president now directly owns 173,756 shares of the company's stock, valued at $10,126,499.68. This represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 21,697 shares of company stock worth $1,276,552 over the last quarter. Company insiders own 2.40% of the company's stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.